# Rebecca Grainger

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rebecca-grainger/

## Facts

| Field | Value |
| --- | --- |
| Citations | 44,686 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 44 |
| i10-index | 105 |
| Last Known Institution | Hutt Hospital |
| OpenAlex ID | https://openalex.org/A5045945972 |
| ORCID iD | https://orcid.org/0000-0001-9201-8678 |
| Works | 254 |

## Researcher papers

- [A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010](https://scholariq.org/papers/a-comparative-risk-assessment-of-burden-of-disease-and-injury-attributable-to-67/)
- [Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry](https://scholariq.org/papers/characteristics-associated-with-hospitalisation-for-covid-19-in-people-with/)
- [Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry](https://scholariq.org/papers/factors-associated-with-covid-19-related-death-in-people-with-rheumatic-diseases/)
- [Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry](https://scholariq.org/papers/associations-of-baseline-use-of-biologic-or-targeted-synthetic-dmards-with-covid/)
- [A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19](https://scholariq.org/papers/a-rush-to-judgment-rapid-reporting-and-dissemination-of-results-and-its/)
- [COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations](https://scholariq.org/papers/covid-19-in-people-with-rheumatic-diseases-risks-outcomes-treatment/)
- [<scp>SARS</scp>–<scp>CoV</scp>‐2 Infection and <scp>COVID</scp>‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis](https://scholariq.org/papers/scp-sars-scp-scp-cov-scp-2-infection-and-scp-covid-scp-19-outcomes-in-rheumatic/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Gout, Hyperuricemia, Uric Acid](https://scholariq.org/topics/gout-hyperuricemia-uric-acid/)
- [Mobile Health and mHealth Applications](https://scholariq.org/topics/mobile-health-and-mhealth-applications/)
- [Innovations in Medical Education](https://scholariq.org/topics/innovations-in-medical-education/)

## Researcher university

- [Hutt Hospital](https://scholariq.org/institutions/hutt-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.